IDH3A: A Potential Drug Target and Biomarker for Cancer (G3419)

Target Name: IDH3A

NCBI ID: G3419

IDH3A

IDH3A: A Potential Drug Target and Biomarker for Cancer

IDH3A (H-IDH alpha), also known as IDH3B (h3.3 IDH), is a protein that is expressed in most tissues of the body. It is a key regulator of the DNA damage response and has been implicated in various diseases, including cancer. In this article, we will discuss the IDH3A protein, its function, potential drug targets, and its potential as a biomarker.

Function and localization

IDH3A is a 21-kDa protein that is expressed in most tissues of the body, including muscle, pancreas, lung, brain, and heart. It is primarily localized to the cytoplasm of cells and is also found in the endoplasmic reticulum (ER) and the nuclear envelope (NE). IDH3A has been shown to localize to the nuclei of actively dividing cells, and its localization is regulated by various factors, including DNA damage, cellular stress, and growth factors.

IDH3A functions as a critical regulator of the DNA damage response (DDR). During DNA damage, IDH3A helps to ensure that the proper repair mechanisms are activated and that the damage is properly logged in the DNA.IDH3A has been shown to play a key role in the regulation of DNA double-strand break repair (DSBR) andIDH3A-mediated homologous recombination (HHR).

IDH3A is also involved in the regulation of cellular stress and has been shown to play a role in the stress response. IDH3A has been shown to be regulated by various stress factors, including temperature, radiation, and chemical stress.

Potential drug targets

IDH3A has been identified as a potential drug target due to its involvement in the regulation of the DNA damage response and its role in various diseases. Several studies have shown that inhibiting IDH3A can lead to a variety of cellular and biological changes, including increased cell proliferation, reduced apoptosis, and increased sensitivity to stress.

One of the potential drug targets for IDH3A is the inhibition of IDH3A-mediated DNA double-strand break repair (DSBR). DSBR is a critical repair mechanism that helps to ensure that DNA double-strand breaks are properly repaired and can prevent the development of cancer. inhibition of IDH3A-mediated DSBR has been shown to lead to increased DNA double-strand break formation and an increased risk of cancer.

Another potential drug target for IDH3A is the inhibition of IDH3A-mediated homologous recombination (HHR). HHR is a critical mechanism for the repair of DNA double-strand breaks and has been shown to be regulated by IDH3A. inhibition of IDH3A-mediated HHR has been shown to lead to decreased DNA double-strand break formation and a reduced risk of cancer.

Potential biomarker

IDH3A has been shown to play a role in the regulation of various cellular processes and has been potential biomarker. Several studies have shown that increasing IDH3A levels can be used as a diagnostic marker for various diseases, including cancer.

One of the potential applications of IDH3A as a biomarker is its ability to be used as a marker for cancer. IDH3A has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. IDH3A has also been shown to be involved in the regulation of cancer cell proliferation and has been shown to play a role in the development

Protein Name: Isocitrate Dehydrogenase (NAD(+)) 3 Catalytic Subunit Alpha

Functions: Catalytic subunit of the enzyme which catalyzes the decarboxylation of isocitrate (ICT) into alpha-ketoglutarate. The heterodimer composed of the alpha (IDH3A) and beta (IDH3B) subunits and the heterodimer composed of the alpha (IDH3A) and gamma (IDH3G) subunits, have considerable basal activity but the full activity of the heterotetramer (containing two subunits of IDH3A, one of IDH3B and one of IDH3G) requires the assembly and cooperative function of both heterodimers

The "IDH3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IDH3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets